Abstract 192P
Background
This study compared the prevalences of metabolic syndrome and of cardiac or kidney comorbidities among patients with hepatocellular carcinoma (HCC) associated with metabolic dysfunction-related fatty liver disease (MAFLD), chronic infection with hepatitis B virus (CHB) or C virus (HCV), or the combination of MAFLD and CHB.
Methods
Medical records were retrospectively analyzed for patients with HCC who underwent hepatectomy at our medical center between March 2013 and March 2023. Patients with HCC of different etiologies were compared in terms of their clinicodemographic characteristics and laboratory data before surgery.
Results
Of the 2422 patients in the analysis, 1,822 were infected with CHB without MAFLD and HCV, 415 had concurrent MAFLD and CHB infection but no HCV infection, 121 had MAFLD without CHB and HCV infection, and 64 were infected with HCV in the presence or absence of MAFLD and CHB. Compared to patients infected with CHB without MAFLD and HCV, those with MAFLD but no CHB and HCV infection showed significantly lower prevalence of cirrhosis, ascites, portal hypertension, alpha-fetoprotein concentration ≥ 400 ng/mL, tumor size > 5 cm, multinodular tumors and microvascular invasion. Conversely, they showed significantly higher prevalence of hypertension, type 2 diabetes, overweight, history of cardiovascular disease, T-wave alterations, hypertriglyceridemia and hyperuricemia, as well as higher risk of arteriosclerotic cardiovascular disease. Compared to patients with MAFLD but no CHB and HCV infection, those with concurrent MAFLD and CHB showed significantly higher prevalence of cirrhosis, ascites and portal hypertension, but significantly lower prevalence of hypertension and history of cardiovascular disease. Compared to patients with other etiologies, those infected with HCV in the presence or absence of MAFLD and CHB, showed significantly higher prevalence of cirrhosis, portal hypertension, ascites, and esophagogastric varices.
Conclusions
Patients with HCC associated with MAFLD tend to have a background of less severe liver disease than those with HCC of other etiologies, but they may be more likely to suffer metabolic syndrome or comorbidities affecting the heart or kidneys.
Legal entity responsible for the study
Hepatobiliary Surgery Department, Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Guangxi Medical University Cancer Hospital, Nanning, China.
Funding
Guangxi Medical University Cancer Hospital.
Disclosure
The author has declared no conflicts of interest.